Targeting the Fibroblast Growth Factor Receptor (FGFR) in Advanced Cholangiocarcinoma: Clinical Trial Progress and Future Considerations.

TAS-120 cholangiocarcinoma debio 1347 derazantinib erdafitinib fibroblast growth factor receptor (FGFR) futibatinib infigratinib pemigatinib

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
03 Apr 2021
Historique:
received: 22 02 2021
revised: 15 03 2021
accepted: 31 03 2021
entrez: 30 4 2021
pubmed: 1 5 2021
medline: 1 5 2021
Statut: epublish

Résumé

Landmark molecular profiling efforts have identified multiple targetable alterations in cholangiocarcinoma. Among the molecular-driven subsets of cholangiocarcinoma, targeting the fibroblast growth factor receptor (FGFR) has shown promise and represents the first targeted therapy to be approved in treatment-refractory, advanced cholangiocarcinoma. In this review, we provide an up-to-date overview of the clinical development of FGFR inhibitors in advanced cholangiocarcinoma. We review the FGFR pathway and discuss emerging issues including resistance to FGFR inhibitors. We end with a discussion on future considerations to optimize the potential of this class of therapeutics in advanced cholangiocarcinoma.

Identifiants

pubmed: 33916849
pii: cancers13071706
doi: 10.3390/cancers13071706
pmc: PMC8038487
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Références

Hepatology. 2014 Apr;59(4):1427-34
pubmed: 24122810
Clin Cancer Res. 2019 Aug 15;25(16):4888-4897
pubmed: 31088831
Cancer Immunol Res. 2019 Sep;7(9):1457-1471
pubmed: 31331945
Cancer Treat Rev. 2016 May;46:51-62
pubmed: 27109926
Oncologist. 2014 Mar;19(3):235-42
pubmed: 24563076
Ther Adv Med Oncol. 2020 Sep 16;12:1758835920953293
pubmed: 32983265
Cytokine Growth Factor Rev. 2020 Apr;52:56-67
pubmed: 31899106
Cytokine Growth Factor Rev. 2005 Apr;16(2):139-49
pubmed: 15863030
Clin Cancer Res. 2018 Sep 1;24(17):4154-4161
pubmed: 29848569
Nat Genet. 2015 Sep;47(9):1003-10
pubmed: 26258846
Nat Genet. 2013 Dec;45(12):1474-8
pubmed: 24185513
Lancet Oncol. 2020 Jun;21(6):796-807
pubmed: 32416072
Nat Rev Gastroenterol Hepatol. 2016 May;13(5):261-80
pubmed: 27095655
Clin Cancer Res. 2019 May 1;25(9):2699-2707
pubmed: 30745300
Crit Rev Oncol Hematol. 2020 Nov;155:103091
pubmed: 32961472
Nat Commun. 2014 Dec 15;5:5696
pubmed: 25526346
Int J Mol Sci. 2020 Sep 18;21(18):
pubmed: 32962091
Best Pract Res Clin Gastroenterol. 2015 Apr;29(2):221-32
pubmed: 25966423
JAMA Oncol. 2015 Jul;1(4):505-27
pubmed: 26181261
Oncotarget. 2019 Mar 22;10(24):2384-2396
pubmed: 31040929
J Clin Oncol. 2018 Jan 20;36(3):276-282
pubmed: 29182496
Liver Cancer. 2020 Jun;9(3):338-357
pubmed: 32647635
JCO Precis Oncol. 2021 Jan 08;5:
pubmed: 34250419
PLoS Genet. 2014 Feb 13;10(2):e1004135
pubmed: 24550739
J Immunother Cancer. 2017 Jul 18;5(1):53
pubmed: 28716061
Gastroenterology. 2013 Apr;144(4):829-40
pubmed: 23295441
Chem Commun (Camb). 2018 Oct 23;54(85):12089-12092
pubmed: 30298149
N Engl J Med. 2019 Jul 25;381(4):338-348
pubmed: 31340094
Liver Int. 2019 May;39 Suppl 1:19-31
pubmed: 30851228
Future Oncol. 2020 Oct;16(30):2385-2399
pubmed: 32677452
Nat Commun. 2015 Jan 22;6:6087
pubmed: 25608663
Lancet Oncol. 2020 May;21(5):671-684
pubmed: 32203698
Cancer Discov. 2017 Oct;7(10):1116-1135
pubmed: 28667006
N Engl J Med. 2005 Feb 24;352(8):786-92
pubmed: 15728811
World J Gastrointest Oncol. 2010 Nov 15;2(11):407-16
pubmed: 21160904
Cancer Discov. 2021 Feb;11(2):326-339
pubmed: 33218975
JCO Precis Oncol. 2018 Nov;2:1-12
pubmed: 35135097
Cancer Discov. 2013 Jun;3(6):636-47
pubmed: 23558953
Cancer Discov. 2017 Mar;7(3):252-263
pubmed: 28034880
Br J Cancer. 2019 Jan;120(2):165-171
pubmed: 30420614
Hepatology. 2018 Sep;68(3):949-963
pubmed: 29278425
Cancer. 2016 Dec 15;122(24):3838-3847
pubmed: 27622582
Cell Rep. 2017 Mar 14;18(11):2780-2794
pubmed: 28297679
Cancer Discov. 2019 Aug;9(8):1064-1079
pubmed: 31109923
Nat Rev Clin Oncol. 2019 Feb;16(2):105-122
pubmed: 30367139
Hum Pathol. 2014 Aug;45(8):1630-8
pubmed: 24837095
Hepatobiliary Surg Nutr. 2017 Apr;6(2):101-104
pubmed: 28503557
Gastroenterology. 2012 Apr;142(4):1021-1031.e15
pubmed: 22178589
Clin Cancer Res. 2019 Aug 1;25(15):4712-4722
pubmed: 31028088
PLoS One. 2014 Dec 23;9(12):e115383
pubmed: 25536104
N Engl J Med. 2010 Apr 8;362(14):1273-81
pubmed: 20375404

Auteurs

Patrick C Lee (PC)

Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.

Andrew Hendifar (A)

Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.

Arsen Osipov (A)

Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.

May Cho (M)

Department of Medicine, UC Davis Comprehensive Cancer Center, Sacramento, CA 95817, USA.
UCI Health Chao Family Comprehensive Cancer Center, University of California Irvine, Orange, CA 92868, USA.

Daneng Li (D)

Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA.

Jun Gong (J)

Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.

Classifications MeSH